Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy

Figure 3

Tang and associates summarized the number of tumor vaccines in each clinical trial phase as of 2018 failed tumor vaccine formulations accounted for 43.1 percent of all clinical trials; only 1.2 percent of tumor vaccine formulations were approved for marketing; most cancer vaccine formulations are in the early stages of clinical trials (Phase I/II).